Our work with both cell and animal models strongly suggested that anti-inflammation treatment could represent a powerful strategy to intervene into disease progression in ALS patients who possess the distinctive mutations in OPTN gene. This evidence concerns the gene OPTN and amyotrophic lateral sclerosis.